Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Sep 10, 2021 11:03am
113 Views
Post# 33839694

RE:Just too bad....

RE:Just too bad....One thing we know, fall (& into winter a bit) will bring clarity one way or another. Right now, it's all about SORT1+ for seeing the possibility of step function gains. NASH is a side project, fairly low expectations, and likely just part of the LSA playbook on education around pipeline. Don't expect much and be surprised if there is anything we don't already know. 

Another reason it's all about SORT1+ is that the 4 investors that came in to lead the ONO are there mostly for cancer. They understand it, know what it can lead to, and are looking to make as much money as they can off their knowledge. They probably don't actually know a whole lot more than we do here. They are looking to also narrow down their list of possible outcomes from failure to success. If the data skews the confidence interval toward success or even just eliminates the negative tail portion heavily, they won't let the opportunity slide by to make even more money on it and will likely start buying with a view that up 15-20-30% is nothing if their models show there's a higher probability of it being worth 3-5x more.  So don't worry about volumes or NASH, worry about getting positive data around SORT1+.  

We will all break the Smile-O-Meter if so.


FredTheVoice wrote: Just too bad you are leaving LEE,

Just a normal and temporary thing whats going on,

Money is sleeping......

Tension is high without news on NASH and CANCER,

Do you remember the level of tension just before TROG approval here......hey....

Lets hope fall will bring clarity very soon,

GLTA

F.


<< Previous
Bullboard Posts
Next >>